Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 8;16:4693–4712. doi: 10.2147/IJN.S314506

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Jin et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

The process of PDT-triggered antitumor T cell responses via immunogenic cell death and the rational strategies to improve antitumor immune responses. PDT killed cells can release cytokines, which stimulate DCs’ maturation. Mature DCs spontaneously migrate to lymph nodes and present antigens to T cells. After antigen-presenting, effector T cells efficiently migrate to tumor sites and kill cells. The rational strategies of promoting PDT-triggered antitumor immunity include combined PDT with ICD-boosted therapies, decrease immunoregulatory suppression with ITM relief, and increase tumor immunogenicity.